Drug Eruptions AND Severe Cutaneous Adverse Reactions — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Drug Eruptions AND Severe Cutaneous Adverse Reactions.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Drug Eruptions AND Severe Cutaneous Adverse Reactions and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Takada T Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches Cureus, 2026.PMID 42465709
[2]Srisuwatchari W, Norchai P Hypersensitivity reactions associated with nutraceuticals and dietary supplements: A narrative review Asian Pac J Allergy Immunol, 2026.PMID 42437383
[3]Mullan KA, Davies S, Teoh K, Tucker HL, et al. Immunological and molecular signatures of carbamazepine-induced maculopapular exanthema Front Immunol, 2026.PMID 42433382
[4]Omran S, Gan SH, Teoh SL Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions Eur J Hum Genet, 2026.PMID 40993225
[5]Wu PC, Chen WT, Huang IH, Chen CB, et al. Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis JAMA Dermatol, 2024.PMID 38568509
[6]Asgarpour JMS, Lam LM, Vogel TK, Goez HR, et al. Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice J Cutan Med Surg, 2021.PMID 32909461
[7]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
[8]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Drug Eruptions AND Severe Cutaneous Adverse Reactions and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Takada T Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches Cureus, 2026.PMID 42465709
[2]Srisuwatchari W, Norchai P Hypersensitivity reactions associated with nutraceuticals and dietary supplements: A narrative review Asian Pac J Allergy Immunol, 2026.PMID 42437383
[3]Mullan KA, Davies S, Teoh K, Tucker HL, et al. Immunological and molecular signatures of carbamazepine-induced maculopapular exanthema Front Immunol, 2026.PMID 42433382
[4]Omran S, Gan SH, Teoh SL Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions Eur J Hum Genet, 2026.PMID 40993225
[5]Wu PC, Chen WT, Huang IH, Chen CB, et al. Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis JAMA Dermatol, 2024.PMID 38568509
[6]Asgarpour JMS, Lam LM, Vogel TK, Goez HR, et al. Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice J Cutan Med Surg, 2021.PMID 32909461
[7]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
[8]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005